LAKI

The BBRC is participating in the international clinical trial b promoted by Eli Lilly and Company, which aims to evaluate the efficacy and safety of remternetug, an anti-amyloid monoclonal antibody, in the very early stages of Alzheimer's disease.

Remternetug is designed to act specifically against a modified form of beta-amyloid known as pyroglutamate Aβ, one of the variants involved in the onset and progression of Alzheimer's, and is administered subcutaneously. This experimental treatment seeks to slow cognitive and functional decline in people at high risk of clinical progression.

In this phase III clinical trial, approximately 1,200 participants will be recruited from more than 250 centers in North America, Latin America, Asia, and two European countries: Spain and the United Kingdom. The study is randomized, double-blind, and placebo-controlled, which means that neither the participants nor the researchers know which treatment each person is receiving during the trial, thus ensuring the scientific validity of the results. Participation in the trial could last up to approximately 5 years, and even some participants who initially received placebo may be eligible for a period of treatment with remternetug in the open-label extension phase (in which both researchers and participants know that they are receiving the study drug).

Thanks to the commitment of our participants, the BBRC has been a leader in the pre-screening of patients.

More official information about this trial is available in the Spanish Registry of Clinical Studies (REEC): LAKI Study – REEC or on the sponsor's website.